SSGJ-611 is under clinical development by 3SBio and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SSGJ-611’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SSGJ-611 overview

Monoclonal antibody is under development for the treatment of autoimmune disorders including atopic dermatitis, chronic sinusitis with nasal polyps, chronic rhinosinusitis (CRS) and chronic obstructive pulmonary disease (COPD). The drug candidate acts by targeting interleukin 4 receptor subunit alpha (IL4R). It is administered through subcutaneous route.

It was under development for asthma.

3SBio overview

3SBio is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology, and other disease conditions. The company distributes its products to hospitals, clinics and dialysis centers in China. The company sells its products in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, the Philippines, Paraguay, Thailand, Trinidad and Tobago. 3SBio is headquartered in Shenyang, Liaoning, China.

For a complete picture of SSGJ-611’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.